Table 13.
Core panel of antimicrobial substances, ECOFFs, CBPs and concentration ranges (in mg/L) for S. aureus
| Antimicrobial | ECOFF[Link] 2012 | CBP[Link] 2012 | Advised 2012 | Decision 2013 | ECOFF 2019 | CBP 2019 | Suggested range, mg/L | Currently available plate format |
|---|---|---|---|---|---|---|---|---|
| Cefoxitin | > 4 | > 4 | > 4 | –a | > 4 | > 4b | 0.5–16 | 0.5–16 |
| Chloramphenicol | > 16 | > 8 | > 16 | – | > 16 | > 8 | 4–64 | 4–64 |
| Ciprofloxacin | > 1 | > 1 | > 1 | – | > 1 | > 1 | 0.25–8 | 0.25–8 |
| Clindamycin | > 0.25 | > 0.5 | > 0.25 | – | > 0.25 | > 0.5 | 0.12–4 | 0.12–4 |
| Erythromycin | > 1 | > 2 | > 1 | – | > 1 | > 2 | 0.25–8 | 0.25–8 |
| Gentamicin | > 2 | – | > 2 | – | > 4 | > 1 | 0.5–16 | 1–16 |
| Linezolid | > 4 | > 4 | > 4 | – | > 4 | > 4 | 1–8 | 1–8 |
| Mupirocin | > 1 | > 256 | > 1 | – | > 1 | NA | 0.5–2256 | 0.5–2256 |
|
Quinupristin/ Dalfopristin |
> 1 | > 2 | > 1 | – | > 1 | > 2 | 0.5–4 | 0.5–4 |
| Sulfamethoxazole | > 128 | > 1024c | > 128 | – | > 128 | NA | 64–512 | 64–512 |
| Tetracycline | > 1 | > 2 | > 1 | – | > 1 | > 2 | 0.5–16 | 0.5–16 |
| Tiamulin | > 2 | – | > 2 | – | > 2 | NA | 0.5–4 | 0.5–4 |
| Trimethoprim | > 2 | > 4 | > 2 | – | > 2 | > 4 | 1–16 | 2–32 |
|
Trimethoprim/ sulfamethoxazoled |
> 0.5 | > 4 | > 0.5 | – | > 0.5 | > 4 | – e | – e |
| Vancomycin | > 2 | > 2 | > 2 | – | > 2 | > 2 | 1–8 | 1–16 |
NA: not available; ECOFF: epidemiological cut‐off value; CBP: clinical breakpoint; MIC: minimum inhibitory concentration.
a
Not included as combination.
b
Not given as a clinical breakpoint by EUCAST, but rather stated that S. aureus with cefoxitin MIC values > 4 are methicillin resistant.
c
Clinical and Laboratory Standards Institute (CLSI).
d
Breakpoint expressed as trimethoprim concentration; trimethoprim:sulfamethoxazole in the ratio 1:19.
e
Not included.
EUCAST ECOFFs and CBPs last accessed on 6.3.2019.